Talphera’s (TLPH) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Talphera (NASDAQ:TLPH) in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a $6.00 price objective on the stock.

Separately, Maxim Group raised shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Performance

Shares of NASDAQ TLPH opened at $0.71 on Tuesday. Talphera has a 52-week low of $0.50 and a 52-week high of $1.61. The company’s 50 day moving average price is $0.65 and its 200-day moving average price is $0.82. The company has a market capitalization of $12.09 million, a P/E ratio of -1.03 and a beta of 0.28.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in shares of Talphera, Inc. (NASDAQ:TLPH) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for approximately 0.4% of Rosalind Advisors Inc.’s portfolio, making the stock its 25th largest holding. Rosalind Advisors Inc. owned 4.47% of Talphera at the end of the most recent reporting period. 37.67% of the stock is currently owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.